Every 8-K that Corbus Pharmaceuticals Holdings, Inc. (CRBP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CRBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRBP filings page.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported positive topline results from its CANYON-1 Phase 1b trial of oral obesity drug candidate CRB-913. The 16‑week, double-blind, placebo-controlled study enrolled 254 obese, non-diabetic adults across 15 U.S. sites, testing 20 mg, 40 mg and 60 mg once-daily doses versus placebo.
The 60 mg dose achieved a 5.0% mean weight loss at 12 weeks versus 0.0% for placebo, with no evidence of plateauing. Among participants completing 60 mg, 44.4% lost at least 5% of baseline weight, 6.7% lost more than 7.5%, and the maximum loss was 13.4%. CRB-913 was generally safe and well tolerated; treatment-emergent psychiatric events were mild to moderate with no suicidality and only one transient depressive symptom in 188 treated participants, and gastrointestinal events were mild or moderate and appeared less frequent than those reported for oral GLP‑1 drugs in cross‑trial comparisons.
The CRB-913 data were selected for a late-breaking presentation at ObesityWeek 2026. Corbus plans to engage the FDA on the development plan and expects to initiate a Phase 2 monotherapy obesity study in the first half of 2027, while also evaluating CRB‑913 combinations with GLP‑1 therapies.
Corbus Pharmaceuticals Holdings reported second-quarter 2026 results and corporate updates, highlighting progress in its oncology and obesity pipeline. The company obtained FDA clearance to proceed with TEMPO-1, a registrational Phase 3 study of CRB-701 in second-line oropharyngeal cancer, and plans to begin enrollment in September 2026. It also completed last patient last visit in the 240-patient CANYON-1 Phase 1b trial of CRB-913 in obesity, with topline data expected in September 2026, and strengthened leadership with a new Chief Medical Officer, Chief Business Officer and Board member.
For the quarter ended June 30, 2026, Corbus recorded a net loss of approximately $35.0 million, or $1.81 per basic and diluted share, compared with a net loss of approximately $17.7 million, or $1.44 per share, a year earlier. Operating expenses rose to approximately $36.2 million from $19.2 million, driven largely by increased clinical development spending, including a $10.0 million milestone payment under the CRB-701 license. Cash, cash equivalents and investments totaled $117.9 million as of June 30, 2026, which Corbus expects will fund operations into 2028 based on current plans.
Corbus Pharmaceuticals appointed Leonardo Viana Nicacio, M.D. as Chief Medical Officer under a two-year employment agreement effective August 3, 2026. His package includes a $545,000 annual base salary, a target bonus of up to 40% of base pay, and equity awards with an aggregate grant date fair value of $2.1 million, split roughly 75% stock options and 25% restricted stock units with multi‑year vesting.
The agreement provides severance of up to 18 months of base salary, COBRA reimbursement and accelerated equity vesting if he is terminated without cause or resigns for good reason during a defined change in control period, subject to a release and non‑compete. Corbus also highlighted upcoming milestones: initiation of the TEMPO‑1 registrational trial of CRB‑701 in second‑line oropharyngeal squamous cell carcinoma in summer 2026, a 250‑patient randomized study targeting overall response rate for potential accelerated approval, a planned similar trial in second‑line cervical cancer, and topline data from the CANYON‑1 Phase 1b obesity study of CRB‑913 in 240 patients expected in late summer 2026, with additional CRB‑701 data in first‑line OPSCC anticipated in early 2027.
Corbus Pharmaceuticals reported updated Phase 1/2 data for its Nectin‑4 antibody‑drug conjugate CRB‑701 in second‑line oropharyngeal head and neck cancer (OPSCC) and cervical cancer. At the 3.6 mg/kg dose, confirmed objective response rates reached 42.9% in OPSCC and 34.4% in cervical cancer, with median durations of response of 6.3 and 8.0 months and progression‑free survival of 5.6 and 4.3 months, respectively.
Across 317 treated patients, CRB‑701 was generally well tolerated, with Grade 3 and 4 adverse events in 19.2% and 0.9%, no Grade 5 events, and treatment discontinuations of 2.8%. Ocular side effects were common but rarely led to discontinuation, and peripheral neuropathy was infrequent and mild.
Corbus plans to start a registrational TEMPO‑1 trial in 2L OPSCC in summer 2026 and has FDA alignment on randomized designs in both 2L OPSCC and 2L cervical cancer, supported by Fast Track designations. The company also highlighted early obesity data for oral CB1 inverse agonist CRB‑913, showing 2.9% placebo‑adjusted weight loss at day 14 in a 150 mg cohort.
Corbus Pharmaceuticals Holdings, Inc. has entered a two‑year employment agreement with Nishant Saxena, appointing him as Chief Business Officer effective May 21, 2026. His package includes a $470,000 base salary, a target bonus up to 40% of salary, and sizable stock‑based incentives.
Saxena will receive 192,300 stock options and 58,300 restricted stock units, with multi‑year vesting and enhanced severance and equity acceleration if he is terminated without cause or leaves for good reason, particularly around a change in control. The company also granted director Brent Pfeiffenberger 24,700 options and 7,500 RSUs under its 2024 Equity Incentive Plan.
Corbus announced a May 26, 2026 conference call and webcast to discuss updated Phase 1/2 data for its Nectin‑4 antibody‑drug conjugate CRB‑701 in head and neck squamous cell carcinoma and cervical cancer, ahead of presentations at the 2026 ASCO Annual Meeting.
Corbus Pharmaceuticals Holdings, Inc. appointed Brent Pfeiffenberger to its Board of Directors, expanding the board to seven members. He is considered independent under Nasdaq rules and will receive a $40,000 annual cash retainer, pro-rated, plus equity awards under the company’s standard non-employee director plan.
Stockholders approved an amendment to the 2024 Equity Compensation Plan to increase the shares of common stock authorized for issuance by 3,000,000 to 5,000,000, and also ratified EisnerAmper LLP as auditor, approved executive compensation on an advisory basis, and chose an annual say-on-pay vote. A press release highlighted upcoming data for oncology candidate CRB-701 and obesity candidate CRB-913, including a planned registrational study for CRB-701 and a 240-patient Phase 1b CANYON-1 study for CRB-913 expected to complete in summer 2026.
Corbus Pharmaceuticals reported first-quarter 2026 results and highlighted progress in its oncology and obesity pipelines. The company posted a net loss of about $23.0 million, or $1.23 per share, on operating expenses of $24.3 million, primarily from higher clinical development spending. Cash, cash equivalents and investments totaled $138.2 million as of March 31, 2026, which Corbus expects will fund operations into 2028.
Corbus reached broad alignment with the FDA on the registration path for CRB-701 in second-line head and neck squamous cell carcinoma and cervical cancer and plans to start a registrational study in second-line HNSCC this summer, with updated monotherapy data to be presented at ASCO 2026. The company also completed enrollment and first visits in its CANYON-1 Phase 1b obesity trial of CRB-913, a peripherally restricted oral CB1 inverse agonist, and expects 16-week data from 240 patients in summer 2026.
Corbus Pharmaceuticals Holdings, Inc. updated its executive employment agreements for CEO Yuval Cohen and CFO Sean Moran, effective April 15, 2026, with terms running through April 15, 2028. Dr. Cohen will receive a base salary of $673,625 with a target bonus of up to 60% of salary, while Mr. Moran will receive $501,273 with a target bonus of up to 40%.
Both executives remain eligible for discretionary equity awards under the company’s equity incentive plans and are subject to non-compete and non-solicitation covenants after employment ends. If terminated without cause or for good reason, each is entitled to cash severance, COBRA reimbursement, and potential pro-rated bonuses, with enhanced cash, bonus, COBRA and full equity vesting protection during a defined change in control period, subject to signing a release and possible reduction to mitigate excise taxes under Section 4999.
Corbus Pharmaceuticals Holdings, Inc. reports that the last patient has been enrolled and completed the first clinical visit in its CANYON-1 Phase 1b trial of CRB-913 for obesity, keeping the study on track for completion in summer 2026. CANYON-1 is a 16-week, double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic participants at multiple U.S. sites. The trial tests once-daily oral CRB-913 at 20 mg, 40 mg, and 60 mg with dose titration from 20 mg, followed by one month of post-dosing monitoring. Earlier Phase 1a data showed CRB-913-treated obese participants achieved a mean 2.9% placebo-adjusted weight loss by Day 14 at 150 mg/day and the drug was reported as safe and well-tolerated, with a favorable gastrointestinal and neuropsychiatric profile.
Corbus Pharmaceuticals Holdings, Inc. announced broad alignment with the U.S. Food and Drug Administration on the registration path for CRB-701, its Nectin-4–targeting antibody drug conjugate, in second-line head and neck squamous cell carcinoma and cervical cancer. The agreed plans call for single, randomized controlled registrational studies in each indication, comparing CRB-701 to physicians’ choice chemotherapy or chemotherapy/Tivdak, with potential accelerated approval based on objective response rate and potential full approval based on overall survival.
The FDA has granted two Fast Track designations to CRB-701 in head and neck squamous cell carcinoma and cervical cancer. Updated Phase 1/2 monotherapy data will be presented at ASCO 2026, and the company anticipates reporting first-line HNSCC combination data with Keytruda in Q4 2026. Corbus expects to initiate a registrational study in second-line HNSCC in mid-2026. The company also disclosed that Chief Medical Officer Dr. Dominic Smethurst will step down effective June 30, 2026, as it adds new senior leaders for the next development phase.
Corbus Pharmaceuticals Holdings, Inc. reported a larger net loss as it advanced its oncology and obesity pipeline and strengthened its balance sheet. Net loss was $20.6 million, or $1.25 per share, for Q4 2025, compared with $9.5 million, or $0.78 per share, a year earlier, driven mainly by higher clinical development spending.
For full-year 2025, net loss was $78.5 million versus $40.2 million in 2024, as research and development expenses more than doubled to $70.1 million. The company ended 2025 with $163.3 million in cash, cash equivalents and investments, and stated this is expected to fund operations into 2028.
Corbus highlighted promising clinical signals from its three key programs. CRB-701, a next‑generation Nectin‑4 antibody‑drug conjugate with FDA Fast Track designations in head and neck squamous cell carcinoma and cervical cancer, showed encouraging Phase 1/2 response rates and a favorable emerging safety profile, with additional monotherapy data and a registrational study update planned for mid‑2026.
CRB-913, an oral CB1 inverse agonist for obesity, produced placebo‑adjusted weight loss of 2.9% over 14 days with favorable gastrointestinal and neuropsychiatric assessments, and a 12‑week, 240‑patient Phase 1b study is expected to complete in summer 2026. The company completed a $75 million public offering in Q4 2025, which it says extended its cash runway into 2028 while it focuses on oncology and obesity opportunities.
Corbus Pharmaceuticals Holdings furnished an updated investor presentation outlining its cash position, pipeline and upcoming milestones. The company reported $173M in cash, cash equivalents and investments as of November 3, 2025, with approximately 17 common shares issued and outstanding and about 20 fully diluted shares.
The presentation highlights three key programs. CRB-701, a next‑generation Nectin‑4 antibody–drug conjugate, showed objective response rates up to 47.6% in head and neck cancer and 55.6% in cervical cancer at the 3.6 mg/kg dose in early studies, with lower rates of peripheral neuropathy and rash than PADCEV in referenced datasets. CRB-913, a peripherally restricted CB1 inverse agonist for obesity, produced 2.9% placebo‑adjusted weight loss by day 14 in a 150 mg multiple‑dose cohort, with no reported nausea, vomiting or constipation in the summarized data.
CRB-601, an anti‑αvβ8 antibody targeting TGFβ activation in solid tumors, is in early clinical development. Corbus outlines planned milestones into 2026, including a Phase 2/3 registrational study for CRB‑701 in head and neck cancer, additional combination data with pembrolizumab, and completion of a 240‑patient Phase 1b obesity study for CRB‑913.
Corbus Pharmaceuticals Holdings, Inc. filed a current report to let investors know that management has updated the company’s investor presentation. The revised presentation is being used to describe its business and is furnished as Exhibit 99.1 to the report. The company notes that this material is being provided under a Regulation FD disclosure item, meaning it is intended to share information broadly with the market. The investor presentation and related materials are furnished rather than filed, so they are not automatically subject to certain liability provisions or incorporated into other securities filings unless specifically referenced.
Corbus Pharmaceuticals Holdings, Inc. announced that long-time board member Alan Holmer has decided to retire from its Board of Directors. He notified the company of his resignation on December 12, 2025, and his service will end effective December 31, 2025. The company states that his decision to step down is due to retirement and is not the result of any disagreement with management or with the company’s operations, policies, or practices. This indicates an orderly governance transition rather than a conflict-driven departure.
Corbus Pharmaceuticals Holdings, Inc. filed a current report describing that it issued a press release on November 12, 2025 with financial information and operating metrics for its fiscal quarter ended September 30, 2025, along with a discussion of its business outlook. The press release is attached as Exhibit 99.1 and is incorporated by reference.
The company notes that the information provided under Items 2.02 and 7.01, including Exhibit 99.1, is being furnished to the SEC and is not deemed filed for liability purposes under the Exchange Act or automatically incorporated into other securities filings, unless specifically referenced.
Corbus Pharmaceuticals (CRBP) entered an underwriting agreement for a public offering of 4,744,231 shares of common stock at $13.00 per share and pre-funded warrants to purchase up to 1,025,000 shares at $12.9999 per warrant. Underwriters also received a 30‑day option to buy up to 865,384 additional shares at the public price.
Corbus expects approximately $70.5 million in net proceeds from the transaction, which is being conducted under an effective Form S‑3 shelf registration. The closing is expected on or about November 3, 2025, subject to customary conditions. The pre-funded warrants are exercisable at any time after issuance, with a 9.99% beneficial ownership cap that holders can adjust up to 19.99% with notice, effective on the 61st day.
The offering terms were described in a final prospectus supplement dated October 30, 2025. The company noted customary representations, indemnities, and termination provisions in the underwriting agreement.
Corbus Pharmaceuticals (CRBP) provided a preliminary financial update for the quarter ended September 30, 2025. Management estimates cash, cash equivalents, and investments of approximately $104.0 million as of September 30, 2025, including $27.0 million in cash and cash equivalents.
These figures are preliminary and unaudited, subject to normal closing procedures and potential adjustments. The company’s independent registered public accounting firm has not audited, reviewed, or compiled this data and offers no assurance. The estimate does not reflect any activity after September 30, 2025, including sales under the company’s Open Market Sale Agreement with Jefferies LLC, as amended. Corbus notes the estimate may change when final results are filed.
Corbus Pharmaceuticals Holdings, Inc. reported that the U.S. Food and Drug Administration has granted Fast Track designation to its drug candidate CRB-701 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in patients previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy. The company disclosed this designation through a current report and attached the related press release as an exhibit.